Expanded Agreement Builds from the Success of its Current Joint Activities in Japan and Singapore, to Bring its Cryoablation Products to Benefit More Patients in Asia
CAESAREA, Israel, Jan. 5, 2021 /PRNewswire/ — IceCure Medical Ltd. (TASE: ICCM), developer of the next generation cryoablation technology that destroys tumors by freezing without the need for surgery, today announced that an expanded distribution agreement in Thailand with its strategic partner, Terumo Corporation (Tokyo: 4543, TRUMY:OTC US), a leading Japanese medical devices company with a global footprint, was signed on December 28, 2020.
The expanded partnership reflects the ongoing success of the initial agreement, which was signed in September 2019, and included distribution rights in Japan and Singapore. The signing of the new multi-million dollar agreement follows IceCure’s earlier Letter of Intent…
